Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study

Results of a study examining ibrutinib as monotherapy and in combination with chemoimmunotherapy for treatment of relapsed mantle cell lymphoma.